Nivolumab
- PDF / 170,122 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 73 Downloads / 170 Views
1 S
Acute coronary syndrome and immune-related colitis: case report A 79-year-old man developed acute coronary syndrome (ACS) and immune-related colitis during treatment with nivolumab for stage II epidermoid lung cancer of no small cells (LCNSC). The man was diagnosed with stage II epidermoid LCNSC. Initially, he was treated with radiotherapy and vinorelbine. Thereafter, he was treated with nivolumab 3 mg/Kg for 2 weeks [route not stated]. He received a total of 10 cycles of nivolumab treatment and achieved stability. However, 10 days after completion of the tenth cycle of nivolumab, he exhibited elevation in segmen T and troponin, consistent with ACS. Therefore, he was admitted to the hospital. The ACS was considered to be secondary to nivolumab. The man was treated with nitroglycerin, enalapril, unspecified androgenic anabolic steroids (AAS), anti-platelet agents and β–blockers. Eventually, improvement in his clinical condition was noted. During hospitalisation, he also developed grade III colitis, which was treated with unspecified systemic corticosteroids. Meanwhile, his diarrhoeal episode resolved and nivolumab treatment was discontinued. Two months later, he was re-admitted due to the grade IV immune-related colitis [duration of treatment to reactions onsets not stated]. Colitis was suspected to be related to colitis. He was then treated with methylprednisolone, tannic-acid [gelatine tannate] and loperamide. However, his condition worsened eventually, and he died 2 days after admission [immediate cause of death not stated]. Cancela-Diez B, et al. Acute coronary sindrome in patient treated with nivolumab: Case report and a bibliographic review. International Journal of Clinical Pharmacy 42: 245 803503022 (plus poster) abstr. HP-PC035, Feb 2020. Available from: URL: http://doi.org/10.1007/s11096-019-00945-w [abstract]
0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 26 Sep 2020 No. 1823
Data Loading...
